AmyPore Alternatives & Competitors
12 companies similar to AmyPore — New target, new paradigm, new strategy that address the root cause of Alzheimer,...
Companies similar to AmyPore
Wren Therapeutics
Stopping the wave of neurodegeneration at its source
Cambridge, United Kingdom
Accera
Pioneering breakthroughs in neurodegenerative therapies for Alzheimer’s, Parkinson’s, and...
Proclara Biosciences
Pioneering therapies to combat neurodegenerative diseases with innovative protein disaggre...
Pangolin Therapeutics, Inc.
New therapeutic agents targeting intrinsically disordered proteins.
United States
Rival Readout
Competing with AmyPore? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Satori Pharmaceuticals
Pioneering advanced therapies for Alzheimer's, Parkinson's, and other neurodegenerative di...
Portugal
Senexis Limited
Small-molecule therapies targeting amyloid protein toxicity
Cambridge, United Kingdom
Treventis Corporation
Treventis | TREVENTIS™ Corporation is an early stage biotechnology company focused on dise...
Toronto, Canada
-logo.jpg "Kineta (Reverse Merger With Yumanity Therapeutics)"){kind=logo}
Kineta (Reverse Merger With Yumanity Therapeutics)
Pioneering new horizons in neurodegenerative disease treatment by addressing protein misfo...
Laminar Pharma
Biopharmaceutical company performing discovery, rational design and initial clinical devel...
Spain
Asceneuron SA
Targeting the root cause of neurodegeneration
Lausanne, Switzerland
About AmyPore
AmyPore is a biotechnology company with a focus on tackling neurodegenerative diseases such as Alzheimer and Parkinson. Founded in 2018 and based in France, the company is built around the groundbreaking work of Pr. Nouara Yahi and Pr.
Development of therapeutic peptides for treating neurodegenerative diseases such as Alzheimer's and Parkinson's
Patients suffering from neurodegenerative diseases, healthcare providers, biotechnology and pharmaceutical companies, research institutions
Neurosciences, Drug Development, Therapeutic Peptides, Molecular Dynamics Simulations, Neurodegenerative Diseases, Proteinopathies, Alzheimer's Disease, Parkinson's Disease, Drug Design, Calcium Imaging, Lipid-protein Interactions, Neurotoxicity, Oligomers
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around AmyPore: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at AmyPore on 11 Jun 2025. The 12 companies listed here were last checked between 11 Sep 2024 and 8 Apr 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
